BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

Supplementary Figure 4



(A) Objective response rate, **(B)** progression-free survival, and **(C)** overall survival to pembrolizumab, in patients with a dNLR <2.6 versus ≥2.6 in the DFCI cohort. **(D)** Objective response rate, **(E)** progression-free survival, and **(F)** overall survival to pembrolizumab, in patients with a dNLR <2.6 versus ≥2.6 in the MGH cohort.